Tiziana Life Sciences Ltd (TLSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) has a cash flow conversion efficiency ratio of -115.846x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.02 Million) by net assets ($52.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TLSA equity financing ratio to measure how much of total assets are equity-financed.
Tiziana Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Tiziana Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TLSA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Tiziana Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tiziana Life Sciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FinLab AG
F:A7A
|
0.013x |
|
Silk Logistics Holdings Ltd
AU:SLH
|
0.381x |
|
Trio-Tech International
NYSE MKT:TRT
|
0.004x |
|
C&C International Corp.
KQ:352480
|
0.045x |
|
Sajo Seafood
KO:014710
|
-0.063x |
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
0.000x |
|
Amir Marketing and Investments in Agriculture Ltd
TA:AMRK
|
-0.002x |
|
Fortifai Ltd
AU:FTI
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Tiziana Life Sciences Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Tiziana Life Sciences Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see TLSA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.00K | $-12.85 Million | -247.058x | -79644.98% |
| 2024-12-31 | $3.94 Million | $-1.22 Million | -0.310x | +86.19% |
| 2023-12-31 | $5.54 Million | $-12.42 Million | -2.244x | -174.65% |
| 2022-12-31 | $19.57 Million | $-15.99 Million | -0.817x | -109.07% |
| 2021-12-31 | $41.28 Million | $-16.13 Million | -0.391x | -178.41% |
| 2020-12-31 | $62.39 Million | $-8.76 Million | -0.140x | -111.09% |
| 2019-12-31 | $-4.18 Million | $-5.29 Million | 1.266x | +114.26% |
| 2018-12-31 | $409.01K | $-3.63 Million | -8.875x | -362.93% |
| 2017-12-31 | $-1.68 Million | $-5.68 Million | 3.375x | +299.20% |
| 2016-12-31 | $3.31 Million | $-5.62 Million | -1.694x | -152.95% |
| 2015-12-31 | $8.50 Million | $-5.70 Million | -0.670x | +48.54% |
| 2014-12-31 | $1.78 Million | $-2.31 Million | -1.302x | -295.67% |
| 2013-12-31 | $-146.00K | $-97.13K | 0.665x | -88.32% |
| 2012-12-31 | $-40.00K | $-227.89K | 5.697x | +439.16% |
| 2011-12-31 | $525.00K | $-881.91K | -1.680x | -148.77% |
| 2010-12-31 | $604.00K | $-407.86K | -0.675x | -52.98% |
| 2009-12-31 | $1.21 Million | $-535.42K | -0.441x | +38.37% |
| 2008-12-31 | $1.34 Million | $-959.80K | -0.716x | +18.70% |
| 2007-12-31 | $2.44 Million | $-2.15 Million | -0.881x | -8.97% |
| 2006-12-31 | $2.43 Million | $-1.96 Million | -0.809x | -92.97% |
| 2005-12-31 | $2.83 Million | $-1.18 Million | -0.419x | +13.69% |
| 2004-12-31 | $3.54 Million | $-1.72 Million | -0.485x | +3.58% |
| 2003-12-31 | $3.03 Million | $-1.52 Million | -0.503x | +29.33% |
| 2002-12-31 | $2.21 Million | $-1.57 Million | -0.712x | +14.07% |
| 2001-12-31 | $2.96 Million | $-2.46 Million | -0.829x | -51.50% |
| 2000-12-31 | $4.01 Million | $-2.19 Million | -0.547x | -106.04% |
| 1999-12-31 | $1.98 Million | $-527.00K | -0.266x | -93.05% |
| 1998-12-31 | $2.25 Million | $-310.00K | -0.138x | -- |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more